ATE433327T1 - Chemisch programmierbare immunität - Google Patents

Chemisch programmierbare immunität

Info

Publication number
ATE433327T1
ATE433327T1 AT00990960T AT00990960T ATE433327T1 AT E433327 T1 ATE433327 T1 AT E433327T1 AT 00990960 T AT00990960 T AT 00990960T AT 00990960 T AT00990960 T AT 00990960T AT E433327 T1 ATE433327 T1 AT E433327T1
Authority
AT
Austria
Prior art keywords
molecule
binding site
immunity
human
sites
Prior art date
Application number
AT00990960T
Other languages
English (en)
Inventor
Kary B Mullis
Original Assignee
Kary B Mullis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kary B Mullis filed Critical Kary B Mullis
Application granted granted Critical
Publication of ATE433327T1 publication Critical patent/ATE433327T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6025—Nucleotides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Residential Or Office Buildings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT00990960T 1999-12-22 2000-12-21 Chemisch programmierbare immunität ATE433327T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17170799P 1999-12-22 1999-12-22
PCT/US2000/035179 WO2001045734A1 (en) 1999-12-22 2000-12-21 Chemically-programmable immunity

Publications (1)

Publication Number Publication Date
ATE433327T1 true ATE433327T1 (de) 2009-06-15

Family

ID=22624828

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00990960T ATE433327T1 (de) 1999-12-22 2000-12-21 Chemisch programmierbare immunität

Country Status (9)

Country Link
US (5) US20030017165A1 (de)
EP (1) EP1242115B1 (de)
AT (1) ATE433327T1 (de)
AU (1) AU3076601A (de)
CA (1) CA2328356A1 (de)
DE (1) DE60042369D1 (de)
DK (1) DK1242115T3 (de)
ES (1) ES2328102T3 (de)
WO (1) WO2001045734A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2328356A1 (en) 1999-12-22 2001-06-22 Itty Atcravi Recreational vehicles
US7645743B2 (en) * 1999-12-22 2010-01-12 Altermune, Llc Chemically programmable immunity
EP2230249A3 (de) 2003-02-06 2010-12-22 ChronTech Pharma AB Antigen/Antikörper oder Ligand/Rezeptor glycosylierter Spezifität Austauscher
US7440877B2 (en) * 2004-03-12 2008-10-21 General Motors Corporation System and method for morphable model design space definition
US20070134259A1 (en) * 2005-11-21 2007-06-14 David Bundle Methods and compositions for pharmacologially controlled targeted immunotherapy
EP1790358A1 (de) * 2005-11-23 2007-05-30 Université de Reims Champagne-Ardennes Proteinkonstrukte designed zum Targeting und Lyse von Zellen
JP2010521526A (ja) * 2007-03-23 2010-06-24 ザ・ガバナーズ・オブ・ザ・ユニバーシティー・オブ・アルバータ 多価ヘテロ二官能性ポリマーおよびその使用方法
CN102459298A (zh) * 2009-05-05 2012-05-16 阿尔特姆恩科技责任有限公司 化学可编程免疫
EP3436585B1 (de) 2016-04-01 2022-07-20 Avidity Biosciences, Inc. Kras-nukleinsäuren und verwendungen davon
WO2017173320A2 (en) 2016-04-01 2017-10-05 Avidity Biosciences Llc Myc nucleic acids and uses thereof
JP2019513371A (ja) 2016-04-01 2019-05-30 アビディティー バイオサイエンシーズ エルエルシー 核酸ポリペプチド組成物とその使用
WO2017173297A1 (en) 2016-04-01 2017-10-05 Avidity Biosciences Llc Beta-catenin nucleic acids and uses thereof
US20170283795A1 (en) 2016-04-01 2017-10-05 Avidity Biosciences Llc Phosphatidylinositol-3-kinase nucleic acids and uses thereof
WO2017173301A1 (en) 2016-04-01 2017-10-05 Avidity Biosciences Llc Egfr nucleic acids and uses thereof
MX2019008199A (es) 2017-01-06 2019-11-25 Avidity Biosciences Llc Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon.
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
EP3691657A4 (de) 2017-10-04 2021-07-21 Avidity Biosciences, Inc. Nukleinsäurepolypeptidzusammensetzungen und verwendungen davon
AU2018378812B2 (en) 2017-12-06 2025-05-22 Avidity Biosciences, Inc. Compositions and methods of treating muscle atrophy and myotonic dystrophy
IL312067B2 (en) 2018-12-21 2025-08-01 Avidity Biosciences Inc Anti-transferrin receptor antibodies and uses thereof
GB201904534D0 (en) 2019-04-01 2019-05-15 Centauri Therapeutics Ltd Novel compounds an therapeutic uses thereof
WO2020219820A1 (en) 2019-04-25 2020-10-29 Avidity Biosciences, Inc. Nucleic acid compositions and methods of multi-exon skipping
CN114375296A (zh) 2019-06-06 2022-04-19 艾维迪提生物科学公司 核酸多肽组合物及其用途
US12006499B2 (en) 2019-06-06 2024-06-11 Avidity Biosciences, Inc. Una amidites and uses thereof
WO2021188390A1 (en) 2020-03-19 2021-09-23 Avidity Biosciences, Inc. Compositions and methods of treating facioscapulohumeral muscular dystrophy
SI4126066T1 (sl) 2020-03-27 2026-04-30 Avidity Biosciences, Inc. Sestavki in postopki zdravljenja mišične distrofije
CN118265544A (zh) 2021-09-16 2024-06-28 艾维迪提生物科学公司 治疗面肩肱型肌营养不良的组合物和方法
EP4735602A2 (de) 2023-06-27 2026-05-06 Atrium Therapeutics, Inc. Zusammensetzungen und verfahren zur verwendung eines auf prkag2 abzielenden antikörper-oligonukleotid-konjugat-abstrahs
AU2024308906A1 (en) 2023-06-30 2026-02-05 Atrium Therapeutics, Inc. Compositions and methods of using pln-targeting antibody-oligonucleotide conjugates
GB202406865D0 (en) 2024-05-15 2024-06-26 Centauri Therapeutics Ltd Novel compounds and therapeutics uses thereof
GB202410052D0 (en) 2024-07-10 2024-08-21 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4169137A (en) * 1974-12-20 1979-09-25 Block Engineering, Inc. Antigen detecting reagents
IL51667A (en) * 1977-03-16 1979-10-31 Miles Yeda Ltd Immunoassay for the determination of a hapten
US5017558A (en) * 1980-01-14 1991-05-21 The Regents Of The University Of California Synthetic vaccine peptide epitomes of hepatitis B surface antigen
US4711955A (en) * 1981-04-17 1987-12-08 Yale University Modified nucleotides and methods of preparing and using same
US4737453A (en) * 1984-12-12 1988-04-12 Immunomedics, Inc. Sandwich immunoassay utilizing a separation specific binding substance
US4637459A (en) * 1985-06-28 1987-01-20 Roussel Louis J Anti rotational device for down hole hydraulic pumping unit
US4940670A (en) * 1986-01-24 1990-07-10 Rhodes Buck A Method for compounding and testing patient specific monoclonal antibodies and monoclonal antibody fragments for in vivo use
SE452065B (sv) * 1986-04-11 1987-11-09 Ulf R Nilsson Antikroppspreparation vars antikroppar er specifika for determinanter i c3 b regionen hos denaturerat humant c3 samt dess anvendning och framstellning
DK8189A (da) * 1988-01-12 1989-07-13 Bunge Australia Antigen-antistof-konjugater, deres fremstilling og anvendelse
US5378815A (en) * 1989-10-20 1995-01-03 National Research Council Canada Process for indirect targeted immunocytolysis
GB8924438D0 (en) 1989-10-31 1989-12-20 Hoffmann La Roche Vaccine composition
US5218088A (en) * 1989-11-02 1993-06-08 Purdue Research Foundation Process for preparing dithiophosphate oligonucleotide analogs via nucleoside thiophosphoramidite intermediates
US6346611B1 (en) * 1990-06-11 2002-02-12 Gilead Sciences, Inc. High affinity TGfβ nucleic acid ligands and inhibitors
US6280932B1 (en) * 1990-06-11 2001-08-28 Gilead Sciences, Inc. High affinity nucleic acid ligands to lectins
US5683867A (en) * 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US6331394B1 (en) * 1991-06-10 2001-12-18 Gilead Sciences, Inc. Nucleic acid ligands to integrins
US6261774B1 (en) * 1990-06-11 2001-07-17 Gilead Sciences, Inc. Truncation selex method
US5962219A (en) * 1990-06-11 1999-10-05 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-selex
US5637459A (en) * 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US5496938A (en) * 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
ES2259800T3 (es) * 1990-06-11 2006-10-16 Gilead Sciences, Inc. Procedimientos de uso de ligandos de acido nucleico.
US6395888B1 (en) * 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
US6344321B1 (en) * 1990-06-11 2002-02-05 Gilead Sciences, Inc. Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
US6232071B1 (en) * 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
US6248332B1 (en) * 1990-10-05 2001-06-19 Medarex, Inc. Targeted immunostimulation with bispecific reagents
WO1992008491A1 (en) 1990-11-20 1992-05-29 Tanox Biosystems, Inc. Conjugates of anti-idiotype antibodies and carriers and their use in epitope-directed immunization
WO1995005454A1 (en) 1992-02-22 1995-02-23 Cambridge Bacteriophage Technologies Ltd. Engineered bacteriophages and vaccines containing them
US6579696B1 (en) * 1992-12-21 2003-06-17 Promega Corporation Polymyxin B conjugates
US6933366B2 (en) * 1996-12-27 2005-08-23 Tripep Ab Specificity exchangers that redirect antibodies to bacterial adhesion receptors
US6040137A (en) * 1995-04-27 2000-03-21 Tripep Ab Antigen/antibody specification exchanger
US6660842B1 (en) * 1994-04-28 2003-12-09 Tripep Ab Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen
SE9401460D0 (sv) * 1994-04-28 1994-04-28 Ferring Ab Antigen/antibody specificity exhanger
US6013443A (en) * 1995-05-03 2000-01-11 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
ATE255910T1 (de) * 1996-04-10 2003-12-15 Sangstat Medical Corp Zellmodulierende konjugate aus elementen aus spezifischen bindungspaaren
WO1998034957A1 (en) * 1997-02-11 1998-08-13 Immunomedics, Inc. STIMULATION OF AN IMMUNE RESPONSE WITH ANTIBODIES LABELED WITH THE α-GALACTOSYL EPITOPE
US6140091A (en) * 1997-06-20 2000-10-31 Boston Biomedical Research Institute Anti-idiotype vaccines to elicit catalytic antibodies
US6054312A (en) * 1997-08-29 2000-04-25 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors
US7112328B2 (en) * 1998-07-16 2006-09-26 Vincent Marinkovich Composition for targeted cell treatment
US6423493B1 (en) * 1998-10-26 2002-07-23 Board Of Regents The University Of Texas System Combinatorial selection of oligonucleotide aptamers
WO2001032207A1 (en) * 1998-10-30 2001-05-10 United States Army Medical Research And Materiel Command Methods for conferring active/passive immunotherapy
US6329145B1 (en) * 1999-02-09 2001-12-11 Gilead Science, Inc. Determining non-nucleic acid molecule binding to target by competition with nucleic acid ligand
US6280943B1 (en) * 1999-06-17 2001-08-28 Gilead Sciences, Inc. 2′-fluoropyrimidine anti-calf intestinal phosphatase nucleic acid ligands
US6387620B1 (en) * 1999-07-28 2002-05-14 Gilead Sciences, Inc. Transcription-free selex
EP1088889A1 (de) 1999-10-01 2001-04-04 University Of Cambridge Rekombinanter doppelt-hybrider filamentöser Bakteriophage
WO2001036448A2 (en) 1999-10-27 2001-05-25 Cel-Sci Corporation Preparation and composition of peptides useful for treatment of autoimmune and transplant related graft versus host conditions
CA2328356A1 (en) 1999-12-22 2001-06-22 Itty Atcravi Recreational vehicles
US7645743B2 (en) 1999-12-22 2010-01-12 Altermune, Llc Chemically programmable immunity
CN1441676B (zh) * 2000-03-31 2012-08-22 普渡研究基金会 用配体-免疫原缀合物治疗的方法
US20030017134A1 (en) * 2001-06-19 2003-01-23 Technion Research And Development Foundation Ltd. Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
US10100316B2 (en) * 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs

Also Published As

Publication number Publication date
US8236321B2 (en) 2012-08-07
US20070148183A1 (en) 2007-06-28
US20090142368A1 (en) 2009-06-04
EP1242115A4 (de) 2004-06-16
WO2001045734A1 (en) 2001-06-28
EP1242115B1 (de) 2009-06-10
US20030017165A1 (en) 2003-01-23
ES2328102T3 (es) 2009-11-10
AU3076601A (en) 2001-07-03
DK1242115T3 (da) 2009-10-05
CA2328356A1 (en) 2001-06-22
DE60042369D1 (de) 2009-07-23
EP1242115A1 (de) 2002-09-25
US7422746B2 (en) 2008-09-09
US7850975B2 (en) 2010-12-14
US20040146515A1 (en) 2004-07-29
US8591910B2 (en) 2013-11-26
US20120276136A1 (en) 2012-11-01

Similar Documents

Publication Publication Date Title
ATE433327T1 (de) Chemisch programmierbare immunität
DE60130256D1 (de) Naphthalinderivate, die sich an den ep4?rezeptor binden
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
EP1027061A4 (de) Iminbildende polysaccharide, deren herstellung und verwendung als zusatzmittel und immunstimulierende mittel
CA2413190A1 (en) Methods for treating rheumatic diseases using a soluble ctla4 molecule
WO2004010957A3 (en) Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
BG64475B1 (bg) Ципразидонови соли
DK1237584T3 (da) Receptorbindende konjugater
BRPI0113286B8 (pt) pirazóis substituídos e composição farmacêutica compreendendo os mesmos.
AR035977A1 (es) Inmunoconjugados de anticuerpos cd44 citotoxicos.
ATE198834T1 (de) Konjugate bestehend aus polysaccharid und protein
DE60033649D1 (de) Verbindungen und therapeutische methoden
DE60113445D1 (de) Substanzen mit verzweigten linkermolekülen
BG102623A (bg) Нови производни на бензоилгуанидина, методи за тяхното получаване и приложението им за производството на ле- карствени средства
DE69921486D1 (de) Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
GB9921592D0 (en) Preparation of highly pure toxin fragments
ITVA20020023A1 (it) Prodotti per l'edilizia a base di idrossialchilguaro purificato
BR0011261B1 (pt) composiÇço oral compreendendo perlita, e, uso de perlita.
ATE441642T1 (de) Hydantoin derivate mit affinität für somatostatin rezeptoren
NO20021573D0 (no) Tverrbundne kopolymerer basert på ikke-tverrbundne polykarboksylkopolymerer
DK0720597T3 (da) Triarylethylenderivater til terapeutisk anvendelse
ID27733A (id) Metoksiminofenilasetamida
FI933506A7 (fi) Bisyklopolyatsamakrosyklokarboksyylihappokomplekseja, niiden konjugaat teja, menetelmä niiden valmistamiseksi ja käyttö varjoaineina
EP1035860A4 (de) Nicht-toxische immun-stimulierende enterotoxin-zusammensetzungen
ES2183543T3 (es) Derivado de tiocolchicosida, su preparacion y su aplicacion en terapeutica.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1242115

Country of ref document: EP

REN Ceased due to non-payment of the annual fee